Press Releases

STEMart Announces Balloon Catheter Testing Services to Ensure Medical Device Safety and Regulatory Compliance

STEMart introduces Balloon Catheter Testing Services for the development of safe and effective medical devices.

Coronado Research announce appointment of Jo Marshall as EVP Data Services and Advanced Analytics

Coronado Research is pleased to announce the appointment of Jo Marshall as EVP of Data Services and Advanced Analytics.

PrecisionLife Appoints Bill Keating as Chief Commercial Officer, Diagnostics and Healthcare

PrecisionLife announces the appointment of Bill Keating as Chief Commercial Officer, Diagnostics and Healthcare.

Leica Biosystems and Indica Labs Announce Significant Strategic Investment and Creation of Digital Pathology Platform

Leica Biosystems and Indica Labs today announced that Leica Biosystems has agreed to make a significant strategic investment in Indica Labs.

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

Vergent Bioscience announced that the U.S. Food & Drug Administration has granted Fast Track designation for the company’s novel, investigational tumor-targeted fluorescent imaging agent, abenacianine for injection (VGT-309), as an adjunct for the intraoperative visualization of primary lung cancer, other pulmonary lesions, cancer containing lymph nodes, and positive surgical margins in patients undergoing surgery for known or suspected cancer in the lung.

ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study

ClearNote Health announced that its Avantect Multi-Cancer Detection Test was selected for the National Cancer Institute’s new Vanguard Study.

ClearNote Health’s Avantect® Test Selected for World’s Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population

ClearNote Health's Avantect Pancreatic Cancer test was selected for a large UK NHS study that will include up to 15,000 patient participants recently diagnosed with type 2 diabetes. The Avantect test is a blood-based assay designed to use key epigenomic and genomic signals to detect the earliest indicators of pancreatic cancer.

Coronado Research announce appointment of Dr Jennifer Bradford as VP, Head of Data Science

Coronado Research announced today that Dr Jennifer Bradford has been appointed as VP, Head of Data Science.

electronRx to Launch purpleDx Pulmonary Disease Smartphone App for Remote Lung Function Monitoring

*Cardiopulmonary assessment tool detects and monitors digital biomarkers to support health management and help improve therapeutic outcomes for chronic respiratory disease patients *electronRx to showcase purpleDx at CES 2025 (7–10 Jan, Las Vegas)

The Institute of Tissue Medicine of the University of Bern Chooses Indica Labs’ HALO AP® to Become the First Public Health Institute in Switzerland to Deploy Digital Pathology for Diagnostics in the Cloud with Amazon Web Services (AWS)

Indica Labs today announces that the Institute of Tissue Medicine and Pathology at the University of Bern has selected HALO AP® for the Institute’s first-in-country digital pathology deployment in the cloud powered by Amazon Web Services, Inc.

PathAI Launches AIM-IHC Breast Panel on AISight® Platform to Streamline Breast Cancer Biomarker Quantification and Improve Pathologist Efficiency

PathAI, a leader in AI-powered pathology solutions, today announced the launch of the AIM-IHC Breast Panel, a set pf advanced AI-assisted, algorithms designed to quantify critical breast cancer biomarkers—HER2, ER, PR, and Ki-67.

Phastar Scoops Prestigious 2024 Scrip Award

Phastar, a global specialist biometrics contract research organization (CRO), has won the Best CRO - Specialist Providers category at the 2024 Scrip Awards.

CB Insights Recognizes Proscia Among Most Promising Digital Health Companies Of 2024

Proscia also ranks as the top vendor in diagnostic digital pathology market landscapes.

Duke Street Bio Announces First Patient Dosed in Phase I Trial with DSB2455, a Next Generation PARP1 Selective Inhibitor for the Treatment of Solid Tumours

Duke Street Bio Ltd has announced that the first patient has been dosed with its highly selective PARP1 inhibitor, DSB2455, in a Phase 1 clinical trial after European Medicines Agency approval earlier this year.

Huateng Pharma Provides PEG-Based Hydrogels for Medical Device Applications

Clinion Wins 2024 SCDM Innovation Award for Excellence in Clinical Data Science

Clinion’s groundbreaking platform is revolutionizing clinical trials, demonstrating how cutting-edge technology is expediting the journey of new therapies to market.

Biopharma PEG Offers 30% Thanksgiving Discount on Monodispersed PEGs

Biopharma PEG Scientific Inc. is offering a 30% Thanksgiving discount on select monodispersed PEGs, including mPEG36-NH2, N3-PEG6-OH, and N3-PEG11-NH2. These high-purity, GMP-grade products are ideal for applications like PEGylation, ADC linkers, and PROTAC linkers. The offer is valid until December 4, 2024, at 23:59 EST. Contact us to take advantage of this limited-time promotion.

CIRCOR’s Highlights BB PEP Series Pumps for Polymer Extrusion

CIRCOR International, Inc., a leading manufacturer and marketer of differentiated technology products and sub-systems, highlights its new BB PEP Series pumps, engineered for high-precision performance in polymer extrusion applications. With a focus on consistent, accurate performance, the BB PEP Series addresses critical demands such as uniformity, durability, and ease of maintenance in the chemical, industrial and life sciences industries.

eClinical Solutions Positioned as Highest Leader in Everest Group’s Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment 2024

Industry recognition highlights company’s diverse portfolio mix, flexibility and ease of deployment, and data integration capabilities, driving real-time review and insights

Beta Bionics Secures $60 Million in Series E Funding to Advance Diabetes Care Innovations

In November 2024, a $60 million fundraising transaction for Series E preferred stock was successfully closed by Beta Bionics, Inc., a trailblazing leader in the creation of cutting-edge diabetes treatment solutions.